Status: Enrolling
Investigator: Dipan Shah
Study Coordinator: Bevin Lopez
Phone: 346.238.5810
This study is designed to evaluate the efficacy of Dotarem enhanced MRI compared to Magnevist and Gadavist enhanced MRI in identifying myocardial infarct. Eighty patients will be recruited for this study. Patients with known CAD and undergoing c ... Read more >
Status: Enrolling
Investigator: Ahmed Gaber
Study Coordinator: Marcos De Oliveira
Phone: 171.344.19837
This is a randomized, double-blind, placebo-controlled trial in de novo kidney transplant patients to determine if the addition of fingolimod (brand name Gilenya®, candidate name- FTY720) on the background of standard immunosuppression will prev ... Read more >
Status: Open Not Enrolling
Investigator: Maen Abdelrahim
Study Coordinator: Safiya Joseph
Phone: 203.308.8567
The purpose of this study is to evaluate the efficacy and safety of NIS793 in combination with gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel and placebo in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC). This st ... Read more >
Status: Enrolling
Investigator: David Victor
Study Coordinator:
Phone:
This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis stage 2 or 3. NASH - Nonalcoholic Steatohepatitis - Drug: IVA337 vs Drug: Placebo This Phase 3 study is conducted to evaluate lanifibranor in adu ... Read more >
Status: Open Not Enrolling
Investigator: David Victor
Study Coordinator: Nicole Hinton
Phone: 281.755.0796
The purpose of this randomized study is to assess safety and effectiveness of BMS-986263 in adults with compensated cirrhosis (chronic liver disease) from nonalcoholic steatohepatitis (fatty liver disease) (NASH). ... Read more >
Status: Open Not Enrolling
Investigator: Sherif Nagueh
Study Coordinator: Nirali Patel
Phone: 713.441.2116
Hypertrophic cardiomyopathy (HCM) is the most common monogenic heart disease and the most frequent cause of sudden cardiac death (SCD) in the young. It is characterized by unexplained left ventricular hypertrophy (LVH), diffuse and patchy fibros ... Read more >
Status: Enrolling
Investigator: Zeenat Safdar
Study Coordinator: Jennifer Lee
Phone: 713.363.7537
This registry will collect data on the strategies used to achieve a diagnosis of Idiopathic Pulmonary Fibrosis (IPF) and Chronic Fibrosing Interstitial Lung Disease with Progressive Phenotype (ILD) and the treatment and management efforts applie ... Read more >
Status: Enrolling
Investigator: David Victor
Study Coordinator: Lindsay Barter
Phone: 502.417.6664
The goals of this clinical study are to learn more about the study drugs, semaglutide (SEMA) with the fixed-dose combination (FDC) of cilofexor/firsocostat (CILO/FIR), and understand whether they cause fibrosis improvement and Nonalcoholic Steat ... Read more >